Navigation Links
CV Therapeutics to Announce 2007 Fourth Quarter and Year End Financial Results on Tuesday, February 26, 2008

PALO ALTO, Calif., Jan. 30 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX) today announced that it will release fourth quarter and year end financial results for 2007 after the market closes on Tuesday, February 26, 2008. Company management will webcast a conference call at 5:00 p.m. EST, 2:00 p.m. PST, on the company's website.

To access the live webcast, please log on to the Company's website at and go to the Investor Information section. Alternatively, domestic callers may participate in the conference call by dialing (866) 524-6247, and international callers may participate in the conference call by dialing (706) 679-3061. Webcast and telephone replays of the conference call will be available approximately two hours after the completion of the call through Tuesday, March 4, 2008. Domestic callers can access the replay by dialing (800) 642-1687, and international callers can access the replay by dialing (706) 645-9291; the PIN access number is 32378484.

About CV Therapeutics

CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases.

CV Therapeutics' approved product, Ranexa(R) (ranolazine extended-release tablets), is indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and should be used in combination with amlodipine, beta-blockers or nitrates.

CV Therapeutics also has other clinical and preclinical drug development candidates and programs, including regadenoson, which is being developed for potential use as a pharmacologic stress agent in myocardial perfusion imaging studies, and CVT-6883, which is being developed as a potential treatment for asthma and other conditions. These product candidates have not been determined by any regulatory authorities to be safe or effective in humans for any use.

Complete prescribing information for Ranexa, including detailed safety and dosage information are available at

SOURCE CV Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Cryo-Cell Announces Research Collaboration Agreement with Saneron CCEL Therapeutics, Inc.
2. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
3. Allos Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
4. Cell Therapeutics, Inc. (CTI) Shareholders Authorize Share Increase at Special Meeting of Shareholders
5. Velcura Therapeutics, Inc. Can Begin Clinical Trials Following Successful Investigational New Drug Application to U.S. FDA
6. Nile Therapeutics Appoints Gregory W. Schafer to Board of Directors
7. Arno Therapeutics Completes License Agreements for the Exclusive Rights to Novel, Targeted Cancer Compounds
8. ImaRx Therapeutics Receives Urokinase Lot Release Approval With Extended Expiration Dating
9. Lorus Therapeutics Appoints Peter Korth as Chief Financial Officer
10. Alba Therapeutics Appoints Wendy Perrow as its Vice President, Marketing and Alliance Management
11. Synvista Therapeutics to Develop Topical Formulation of ALT-2074 for the Treatment of Psoriasis
Post Your Comments:
(Date:11/25/2015)... Md. , Nov. 25, 2015  PharmAthene, Inc. ... Directors has adopted a stockholder rights plan (Rights Plan) ... net operating loss carryforwards (NOLs) under Section 382 of ... --> PharmAthene,s use of its NOLs ... "ownership change" as defined in Section 382 of the ...
(Date:11/25/2015)... Nov. 25, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: ... business and prospects remain fundamentally strong and highlights ... doxorubicin) recently received DSMB recommendation to continue the ... review of the final interim efficacy and safety ... Endpoint in men with heavily pretreated castration- and ...
(Date:11/24/2015)... KUALA LUMPUR, Malaysia , Nov. 24, 2015 ... the global contract research organisation (CRO) market. The ... to result in lower margins but higher volume ... With increased capacity and scale, however, margins in ... Contract Research Organisation (CRO) Market ( ...
(Date:11/24/2015)... Worcester, Mass. (PRWEB) , ... November 24, 2015 ... ... need to maintain healthy metabolism. But unless it is bound to proteins, copper ... Institutes of Health (NIH), researchers at Worcester Polytechnic Institute (WPI) will conduct a ...
Breaking Biology Technology:
(Date:11/17/2015)... November 17, 2015 Paris ... 2015.  --> Paris , qui ... DERMALOG, le leader de l,innovation biométrique, a inventé ... passeports et empreintes sur la même surface de balayage. ... et l,autre pour les empreintes digitales. Désormais, un seul ...
(Date:11/12/2015)...  A golden retriever that stayed healthy despite having ... provided a new lead for treating this muscle-wasting disorder, ... of MIT and Harvard and the University of São ... Cell, pinpoints a protective gene that boosts ... The Boston Children,s lab of Lou Kunkel , ...
(Date:11/10/2015)... 10, 2015  In this report, the ... of product, type, application, disease indication, and ... report are consumables, services, software. The type ... biomarkers, efficacy biomarkers, and validation biomarkers. The ... diagnostics development, drug discovery and development, personalized ...
Breaking Biology News(10 mins):